Siirry sisältöön

Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN

Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field. Backed by their common shareholder, Keensight Capital, one …

Biovian has been recognized as Turku Developer 2023

Junior Chamber International (JCI) Turku has recognized Biovian as the Turku Developer 2023. We are delighted and honored to announce that Biovian has received the Turku Developer 2023 award by JCI Turku, Finland on Friday, …

Biovian unveils the stonemasonry work of GeneCity facility

Biovian, a leading biopharmaceutical CDMO from Finland, uncovers the stonemasonry work of its new manufacturing facility, GeneCity. Located in a growing technology hub at Turku, Kupittaa, the state-of-the-art facility houses a blend of cutting-edge equipment …

Biovian’s growth story featured in Business Focus Magazine

We invite you to explore the recent article “Next Level Biopharmaceuticals” featured in the Business Focus Magazine’s latest issue. Business Focus Magazine interviewed Biovian’s CEO and co-founder Antti Nieminen about Biovian’s growth story and position …

Biovian at 26th Annual ASGCT Meeting in May 16-20, 2023

Biovian will be exhibiting at the 26th Annual ASGCT Meeting held in Los Angeles, in May 16-20, 2023. Meet the Biovian representatives Magnus Gustafsson CBO, Eero Mustalahti Head of Business Development and Taru Värri Marketing …
BIO2022 convention. Meet Biovian at booth 848

BIO International Convention June 13, 2022

Biovian is looking forward to participating in the BIO International Convention on June 13th-16th in San Diego. #BIO2022 is back in person. Biovian representatives, CBO Magnus Gustafsson and Head of Business Development Eero Mustalahti are …
BIO-CDMO with high NPS

How does a CDMO achieve a high net promoter score?

Biovian, a Finnish Contract Development and Manufacturing Organization, CDMO, has year after year received a high net promoter score, NPS. NPS measures customer satisfaction and loyalty by asking clients how likely they are to recommend …
Antti Nieminen Biovian CEO

Biovian Announces Antti Nieminen as Chief Executive Officer

Biovian Oy announces that its Board of Directors has named Antti Nieminen, as a Chief Executive Officer, effective January 1st, 2022. Nieminen succeeds Co-Founder Dr. Knut Ringbom, who will transition to Senior Advisor of Biovian, …
Magnus Gustafsson from Biovian gave a talk about gene therapy

Biovian in New Horizons in Biologics & Bioprocessing

New Horizons 2021 event took place on December 9th in Stockholm. Dr. Magnus Gustafsson from Biovian gave a talk about “Gene therapy today and tomorrow.”  New Horizons is an international educational forum that focuses on …
Press Release_Lokon Pharma selects Biovian as a CDMO

Lokon Pharma AB signs an agreement with Biovian

Lokon Pharma AB, a company developing next-generation cancer therapeutics, has selected Biovian Oy as a CDMO partner for GMP manufacturing of LOAd703 for a pivotal randomized study. The uniquely engineered LOAd703 oncolytic virus is currently …
BLOG Viral Vectors and gene therapy basics summarized

Viral Vector and gene therapy basics summarized

Here we present some basic concepts of Viral Vectors used in gene therapy applications with special focus on AAV and Adenovirus vectors. Please proceed to this page if you are looking for information about our …
Adenovirus vector GMP manufacturing_blog

Adenovirus vector GMP manufacturing in adherent cell cultures and suspension cell cultures.

Adenoviruses are among the most attractive Viral Vectors for gene therapy because of their well-defined biology and characteristics. They have a high packaging capacity and can accommodate large transgene inserts of sizes up to ~8 kb. Adenovirus vectors also have high transduction efficiency and they can infect both dividing and non-dividing cells in a broad range of cell and tissue …